In-Depth Characterization of the MicroRNA Transcriptome in Normal Thyroid and Papillary Thyroid Carcinoma

Świerniak, Michał; Wójcicka, Anna; Czetwertyńska, Małgorzata; Stachlewska, Elżbieta; Maciąg, Monika; Wiechno, W; Górnicka, Barbara; Bogdańska, Magdalena; Koperski, Łukasz; Chapelle, Albert de la; Jażdżewski, Krystian

doi:10.1210/jc.2013-1214

Cited by 128 publications

(125 citation statements)

References 33 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…The studies showed that different cancer types exhibit deregulation of different microRNAs, proving the existence of cancer-specific signatures of microRNA expression (20,21,22,23,24). These observations were recently confirmed in the next-generation sequencing of thyroid tumors (19,25). The studies showed that PTC is accompanied by a significant upregulation of the miR-146, -181, -221/222, and -224 families; follicular thyroid carcinoma (FTC) exhibits upregulation of the miR-181 and -200 families and downregulation of the miR-199 family, and anaplastic thyroid carcinoma (ATC) is characterized by elevated levels of miR-17 and -221/222 and downregulation of the let-7 and miR-30 and -29 families.…”

Section: Micrornas Of the Thyroid Glandmentioning

confidence: 74%

“…A recent next-generation sequencing study revealed that although 2588 human microRNAs are deposited in miRbase 21 (18), only 427 miRs are expressed at a significant level (O5 reads per million reads (RPMs)) in the thyroid gland (19). The study also showed that the 427 thyroid miRs exist in 1749 length isoforms, and novel isomiRs are often expressed at higher levels compared to their canonical counterparts.…”

Section: Micrornas Of the Thyroid Glandmentioning

confidence: 99%

“…In papillary thyroid carcinoma (PTC), 427 expressed miRs created almost 100 novel regulatory seeds, while the total number reached 513. Even though the expression of a single microRNA can be relatively low, the action of all isoforms carrying the same seed region (so-called seed power) can induce strong biological responses (19). The role of microRNAs in thyroid tumors has been studied for a long time, revealing specific expression patterns of miRs.…”

Section: Micrornas Of the Thyroid Glandmentioning

confidence: 99%

See 2 more Smart Citations

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Wójcicka

Kolanowska

Jażdżewski

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

MicroRNAs, short non-coding regulators of the gene expression, are subjects of numerous investigations assessing their potential use in the diagnostics and management of human diseases. In this review, we focus on studies that analyze the utility of microRNAs as novel diagnostic and therapeutic tools in follicular cell-derived thyroid carcinomas. This very interesting and promising field brings new insight into future strategies for personalized medicine.

show abstract

Section: Micrornas Of the Thyroid Glandmentioning

confidence: 74%

Section: Micrornas Of the Thyroid Glandmentioning

confidence: 99%

Section: Micrornas Of the Thyroid Glandmentioning

confidence: 99%

See 1 more Smart Citation

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Wójcicka

Kolanowska

Jażdżewski

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…They reported different miRNAs expression between cell lines subpopulations from human PTC with lymph node involvement showing increasing metastatic potency, compared with their control subpopulations. As consistently reported by a wide set of studies (He et al 2005, Pallante et al 2006, Tetzlaff et al 2007, Nikiforova et al 2008, Swierniak et al 2013, upregulation of miR146b and the miR-221/miR-222 cluster represent the most frequent miRNA alterations related to PTC, and this has been definitely confirmed by the recent deep-sequencing analysis of the largest cohort assessed to date (Mancikova et al 2015). Therefore, many authors have searched for a possible association between the mentioned miRNAs and clinical outcome in DTC.…”

Section: :11mentioning

confidence: 70%

Application of molecular biology of differentiated thyroid cancer for clinical prognostication

Marotta¹,

Sciammarella²,

Colao³

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Although cancer outcome results from the interplay between genetics and environment, researchers are making a great effort for applying molecular biology in the prognostication of differentiated thyroid cancer (DTC). Nevertheless, role of molecular characterisation in the prognostic setting of DTC is still nebulous. Among the most common and well-characterised genetic alterations related to DTC, including mutations of BRAF and RAS and RET rearrangements, BRAF V600E is the only mutation showing unequivocal association with clinical outcome. Unfortunately, its accuracy is strongly limited by low specificity. Recently, the introduction of next-generation sequencing techniques led to the identification of TERT promoter and TP53 mutations in DTC. These genetic abnormalities may identify a small subgroup of tumours with highly aggressive behaviour, thus improving specificity of molecular prognostication. Although knowledge of prognostic significance of TP53 mutations is still anecdotal, mutations of the TERT promoter have showed clear association with clinical outcome. Nevertheless, this genetic marker needs to be analysed according to a multigenetic model, as its prognostic effect becomes negligible when present in isolation. Given that any genetic alteration has demonstrated, taken alone, enough specificity, the co-occurrence of driving mutations is emerging as an independent genetic signature of aggressiveness, with possible future application in clinical practice. DTC prognostication may be empowered in the near future by non-tissue molecular prognosticators, including circulating BRAF V600E and miRNAs. Although promising, use of these markers needs to be refined by the technical sight, and the actual prognostic value is still yet to be validated. 23:11Review V Marotta et al. Molecular prognosis in thyroid cancer

show abstract

“…In TC, differences in miRNA expression profiles are associated with tumor histology and have emerged as potential biomarkers to distinguish between (1) PTC vs normal thyroid tissue (He et al 2005, Pallante et al 2006, Tetzlaff et al 2007, (2) benign follicular adenoma versus malignant FTC (Rossing et al 2012) and (3) classical FTC vs oncocyticvariant FTC (Nikiforova et al 2008). Predominantly, the miRNAs miR-146b, miR-181b, miR-221, miR-222 and miR-224 are highly upregulated in PTC as compared to normal thyroid tissue (Agretti et al 2012, Dettmer et al 2013, Swierniak et al 2013, Acibucu et al 2014. In contrast, predictive miRNA biomarkers for FTC are upregulation of miR-181 and miR-200 and downregulation of miR-199 (Mancikova et al 2015).…”

Section: Transcriptional Regulation By Mirnasmentioning

confidence: 99%

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer

Tesselaar¹,

Smit

Nagarajah³

et al. 2017

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

While in most patients with non-medullary thyroid cancer (TC), disease remission is achieved by thyroidectomy and ablation of tumor remnants by radioactive iodide (RAI), a substantial subgroup of patients with metastatic disease present tumor lesions that have acquired RAI resistance as a result of dedifferentiation. Although oncogenic mutations in BRAF, TERT promoter and TP53 are associated with an increased propensity for induction of dedifferentiation, the role of genetic and epigenetic aberrations and their effects on important intracellular signaling pathways is not yet fully elucidated. Also immune, metabolic, stemness and microRNA pathways have emerged as important determinants of TC dedifferentiation and RAI resistance. These signaling pathways have major clinical implications since their targeting could inhibit TC progression and could enable redifferentiation to restore RAI sensitivity. In this review, we discuss the current insights into the pathological processes conferring dedifferentiation and RAI resistance in TC and elaborate on novel advances in diagnostics and therapy to improve the clinical outcome of RAI-refractory TC patients.

show abstract

In-Depth Characterization of the MicroRNA Transcriptome in Normal Thyroid and Papillary Thyroid Carcinoma

Abstract: Almost all microRNAs exhibit isoforms of variable length and potentially distinct function in thyroid tumorigenesis.

Cited by 128 publications

References 33 publications

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer

Application of molecular biology of differentiated thyroid cancer for clinical prognostication

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer

Contact Info

Product

Resources

About